| . "Checking semiparametric transformation models with censored data.." Biostatistics. 2012;13(1):18-31. Pub Med |
| . "Semiparametric regression for the weighted composite endpoint of recurrent and terminal events.." Biostatistics. 2016;17(2):390-403. Pub Med |
| . "Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.." Biostatistics. 2011;12(2):258-69. Pub Med |
| . "Bayesian methods in clinical trials: A Bayesian analysis of ECOG trials E1684 and E1690.." BMC Med Res Methodol. 2012;12():183. Pub Med |
| . "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(-) breast cancer that had progressed during or after prior endocrine therapy.." Breast Cancer Res. 2017;19(1):18. Pub Med |
| . "Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.." Breast Cancer Res Treat. 2017;166(1):167-177. Pub Med |
| . "Pathway-based identification of SNPs predictive of survival.." Eur J Hum Genet. 2011;19(6):704-9. Pub Med |
| . "Associating somatic mutations to clinical outcomes: a pan-cancer study of survival time.." Genome Med. 2019;11(1):37. Pub Med |
| . "A counterfactual p-value approach for benefit-risk assessment in clinical trials.." J Biopharm Stat. 2015;25(3):508-24. Pub Med |
| . "Optimal estimation for regression models on τ-year survival probability.." J Biopharm Stat. 2015;25(3):539-47. Pub Med |
| . "Biomarker threshold adaptive designs for survival endpoints.." J Biopharm Stat. 2018;28(6):1038-1054. Pub Med |
| . "Statistical methods for conditional survival analysis. ." J Biopharm Stat. 2018;28(5):927-938. Pub Med |
| . "Basic concepts and methods for joint models of longitudinal and survival data.." J Clin Oncol. 2010;28(16):2796-801. Pub Med |
| . "Multitrial evaluation of progression-free survival as a surrogate end point for overall survival in first-line extensive-stage small-cell lung cancer.." J Thorac Oncol. 2015;10(7):1099-106. Pub Med |
| . "A regularized variable selection procedure in additive hazards model with stratified case-cohort design.." Lifetime Data Anal. 2018;24(3):443-463. Pub Med |
| . "Proportional exponentiated link transformed hazards (ELTH) models for discrete time survival data with application.." Lifetime Data Anal. 2016;22(1):38-62. Pub Med |
| . "Accelerated failure time model for data from outcome-dependent sampling.." Lifetime Data Anal. 2021;27(1):15-37. Pub Med |
| . "Estimation of treatment effects and model diagnostics with two-way time-varying treatment switching: an application to a head and neck study.." Lifetime Data Anal. 2020;26(4):685-707. Pub Med |
| . "Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching.." Lifetime Data Anal. 2014;20(1):76-105. Pub Med |
| . "Optimal treatment regimes for survival endpoints using a locally-efficient doubly-robust estimator from a classification perspective.." Lifetime Data Anal. 2017;23(4):585-604. Pub Med |
| . "Reweighted estimators for additive hazard model with censoring indicators missing at random.." Lifetime Data Anal. 2018;24(2):224-249. Pub Med |
| . "Joint modeling of survival time and longitudinal outcomes with flexible random effects.." Lifetime Data Anal. 2018;24(1):126-152. Pub Med |
| . "Validation of progression-free survival as a surrogate endpoint for overall survival in malignant mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.." Oncologist. 2017;22(2):189-198. Pub Med |
| . "Sample size calculation for studies with grouped survival data.." Stat Med. 2018;37(27):3904-3917. Pub Med |
| . "Responses to discussants of 'Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group'.." Stat Med. 2015;34(14):2202-3. Pub Med |
| . "Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates.." Stat Med. 2014;33(26):4560-76. Pub Med |
| . "Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.." Stat Med. 2011;30(13):1502-18. Pub Med |
| . "Sample size and power determination in joint modeling of longitudinal and survival data.." Stat Med. 2011;30(18):2295-309. Pub Med |
| . "Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group.." Stat Med. 2015;34(14):2181-95. Pub Med |
| . "Subgroup detection and sample size calculation with proportional hazards regression for survival data.." Stat Med. 2017;36(29):4646-4659. Pub Med |
| . "Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.." Stat Med. 2014;33(27):4715-33. Pub Med |
| . "Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION).." Am Heart J. 2013;165(2):193-9. Pub Med |
| . "Survival benefit of lung transplantation in the modern era of lung allocation.." Ann Am Thorac Soc. 2017;14(2):172-181. Pub Med |
| . "Assessing the causal effect of organ transplantation on the distribution of residual lifetime.." Biometrics. 2013;69(4):820-9. Pub Med |
| . "Ten-year experience with extended criteria cardiac transplantation.." Circ Heart Fail. 2013;6(6):1230-8. Pub Med |
| . "Predictive blood-based biomarkers in patients with epithelial ovarian cancer treated with carboplatin and paclitaxel with or without bevacizumab: Results from GOG-0218.." Clin Cancer Res. 2020;26(6):1288-1296. Pub Med |
| . "Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer.." Clin Cancer Res. 2020;26(1):82-92. Pub Med |
| . "Power and sample size calculations for SNP association studies with censored time-to-event outcomes.." Genet Epidemiol. 2012;36(6):538-48. Pub Med |
| . "I-Boost: An integrative boosting approach for predicting survival time with multiple genomics platforms.." Genome Biol. 2019;20(1):52. Pub Med |
| . "On sample size calculation for comparing survival curves under general hypothesis testing.." J Biopharm Stat. 2012;22(3):485-95. Pub Med |
| . "Optimal two-stage log-rank test for randomized phase II clinical trials.." J Biopharm Stat. 2017;27(4):639-658. Pub Med |
| . "Clinical prognostic model for older patients with advanced non-small cell lung cancer.." J Geriatr Oncol. 2019;10(4):555-559. Pub Med |
| . "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.." Lancet Oncol. 2017;18(6):732-742. Pub Med |
| . "On optimal treatment regimes selection for mean survival time.." Stat Med. 2015;34(7):1169-84. Pub Med |
| . "Multicategory reclassification statistics for assessing improvements in diagnostic accuracy.." Biostatistics. 2013;14(2):382-94. Pub Med |
| . "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.." Lancet Oncol. 2017;18(6):732-742. Pub Med |
| . "Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.." Pharmacogenomics. 2013;14(5):555-74. Pub Med |
| . "Biclustering via sparse clustering.." Biometrics. 2020;76(1):348-358. Pub Med |
| . "Parameter estimation in Cox models with missing failure indicators and the OPPERA study.." Stat Med. 2015;34(30):3984-96. Pub Med |
| . "On model selections for repeated measurement data in clinical studies.." Stat Med. 2015;34(10):1621-33. Pub Med |
